Awards made under Performance Share Plan

RNS Number : 7763L
e-Therapeutics plc
09 July 2014
 



e-Therapeutics plc ("e-Therapeutics" or the "Company")

Awards made under the e-Therapeutics Performance Share Plan 2013 
(the "Performance Share Plan")

Oxford and Newcastle, UK, 9 July 2014 - e-Therapeutics (AIM:ETX) announces that various awards were made to Directors and other employees on 8 July 2014 under the Performance Share Plan, as set out in the tables below.  All awards (which are either basic or supplementary awards) take the form of options to acquire, at par, ordinary shares of 0.1p each ("Shares"), with vesting subject to certain performance criteria.  

Vesting of all awards under the Performance Share Plan is based on the extent to which the average closing share price of a Share during the 20 dealing days ending on the third anniversary of the Effective Date (as set out below) or, in the event of an earlier change of control of the Company, the price offered by the party acquiring control of the Company (in each case the "Closing Price"), exceeds the average closing share price of a Share during the 20 dealing days prior to the Effective Date (the "Opening Price").  Vested awards may only be exercised on or after the earlier of (a) the third anniversary of the making of the awards (i.e. 8 July 2017) and (b) a change of control of the Company.

For basic awards, 25% of Shares the subject of awards will vest if the Closing Price exceeds the Opening Price by 25%, and vesting will increase pro-rata up to 100% of the award where the Closing Price exceeds the Opening Price by 100% or more.  For supplementary awards, vesting will occur only if the Closing Price exceeds the Opening Price by 150% or more.

The third table below indicates the relevant Closing Prices.

Directors' Awards:

Name of Director

Effective Date (for performance measures)

Total Number

17 October 2013

7 April 2014

24 June 2014

(as % of Issued Share Capital)

Basic Award

Supplementary Award

Basic Award

Supplementary
 Award

Basic Award

Supplementary
Award

Total Options after this grant

Total Shares held

Malcolm Young

0

0

0

0

627,272

627,272

1,938,934
(0.73%)

20,644,958
(7.82%)

Stephen Self

310,000

310,000

0

0

363,636

363,636

2,756,432* (1.04%)

273,577
(0.10%)

Steve Medlicott

0

0

250,000

250,000

272,727

272,727

1,045,454 (0.40%)

100,000
(0.04%)

* includes an interest in 113,049 options in issue held by Mr Self's wife, who is an employee of the Company.

 

Awards to Other Employees:

Effective Date

17 October 2013

24 June 2014

Basic
Award

Supplementary
Award

Basic Award

Supplementary
Award

654,763

327,375

819,128

409,558

 

As at the date of this announcement, and following the above, there are outstanding options, awards and warrants over 10,914,757 Shares, amounting to approximately 3.50% of the Company's current issued share capital.

Opening Prices and Closing Prices for vesting against performance criteria:

Effective Date

Opening Price

Basic award

Supplementary award



Closing Price exceeds Opening Price by 25%

Closing Price exceeds Opening Price by 100%

Closing Price exceeds Opening Price by 150%

17 October 2013

32.2875 pence

40.359375 pence

64.75 pence

80.71875 pence

7 April 2014

21.8375 pence

27.296875 pence

43.765 pence

54.59375 pence

24 June 2014

28.075 pence

35.09375 pence

56.15 pence

70.1875 pence

 

-Ends-

 

Contacts:

 

e-Therapeutics plc

Steve Medlicott, Finance Director

Tel: +44 (0) 1993 883125

www.etherapeutics.co.uk 

 

N+1 Singer

Aubrey Powell / Jen Boorer

Tel: +44 (0)20 7496 3000

www.n1singer.com 

 

Instinctif Partners

Melanie Toyne-Sewell / Emma Barlow

Tel: +44 (0) 20 7457 2020

Email: e-therapeutics@instinctif.com

 

About e-Therapeutics plc

e-Therapeutics is an AIM-quoted drug discovery and development company with a proprietary platform in network pharmacology, an innovative new approach to drug discovery based on advances in network science and chemical biology. The Company's discovery and development activity is currently focused in cancer and disorders of the nervous system.


e-Therapeutics is based at sites in Oxford and Newcastle, UK. For more information about the Company, please visit
www.etherapeutics.co.uk.

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSUGURUMUPCGAR
UK 100

Latest directors dealings